{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:54Z","timestamp":1781650854914,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Project of Guangdong Provincial Department of Finance","award":["No. KS0120220269"],"award-info":[{"award-number":["No. KS0120220269"]}]},{"name":"The Project of Guangdong Provincial Department of Finance","award":["No.KS0120220272"],"award-info":[{"award-number":["No.KS0120220272"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02153-x","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:05:24Z","timestamp":1777356324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant hormone therapy plus robot-assisted radical prostatectomy improves pathologic outcomes in high-risk prostate cancer: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Junhong","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Xv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiumin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"2","key":"2153_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/pros.24817","volume":"85","author":"HY Tao","year":"2025","unstructured":"Tao HY, Wu F, Li R, et al. Efficacy and predictive factors analysis of androgen deprivation plus novel hormone therapy as neoadjuvant treatment for high-risk prostate cancer. Prostate. 2025;85(2):198\u2013206.","journal-title":"Prostate"},{"key":"2153_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149:778\u201389.","journal-title":"Int J Cancer"},{"issue":"1","key":"2153_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00345-024-05412-4","volume":"43","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhou F, Lu T, et al. Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: A multicenter, open-label, single-arm, phase II trial. World J Urol. 2025;43(1):58\u201367.","journal-title":"World J Urol"},{"issue":"12","key":"2153_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","volume":"18","author":"G Devos","year":"2021","unstructured":"Devos G, Devlies W, Meerleer GD, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021;18(12):739\u201362.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"2153_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/pcan.2016.40","volume":"19","author":"R Mano","year":"2016","unstructured":"Mano R, Eastham J, Yossepowitch O. The very-high-risk prostate cancer: a contemporary update. Prostate Cancer Prostatic Dis. 2016;19(4):340\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"2153_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/JU.0000000000002250","volume":"207","author":"F Chierigo","year":"2022","unstructured":"Chierigo F, Wenzel M, W\u00fcrnschimmel C, et al. Survival after radical prostatectomy versus radiation therapy in high-risk and very high-risk prostate cancer. J Urol. 2022;207(2):375\u201384.","journal-title":"J Urol"},{"issue":"1","key":"2153_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","volume":"35","author":"MD Shelley","year":"2009","unstructured":"Shelley MD, Kumar S, Wilt T, et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9\u201317.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2153_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41585-018-0017-x","volume":"15","author":"G Pignot","year":"2018","unstructured":"Pignot G, Maillet D, Gross E, et al. Systemic treatments for high-risk localized prostate cancer. Nat Rev Urol. 2018;15(8):498\u2013510.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"2153_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cncr.10657","volume":"95","author":"AV D\u2019Amico","year":"2002","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95(2):281\u20136.","journal-title":"Cancer"},{"issue":"2","key":"2153_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.6004\/jnccn.2010.0010","volume":"8","author":"JL Mohler","year":"2010","unstructured":"Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010;8(2):145.","journal-title":"J Natl Compr Canc Netw"},{"key":"2153_CR11","doi-asserted-by":"crossref","unstructured":"Gillessen S, Bossi A, Davis ID et al. Management of patients with advanced prostate cancer. Part I: Intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. Eur Urol. 2023; 83(3):267\u2013293.","DOI":"10.1016\/j.eururo.2022.11.002"},{"issue":"1","key":"2153_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JU.0000000000001702","volume":"206","author":"RR McKay","year":"2021","unstructured":"McKay RR, Xie W, Ye H, et al. Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. J Urol. 2021;206(1):80\u20137.","journal-title":"J Urol"},{"issue":"1","key":"2153_CR13","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42\u201350.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2153_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/codi.13207","volume":"18","author":"JE Ryan","year":"2016","unstructured":"Ryan JE, Warrier SK, Lynch AC, et al. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016;18(3):234\u201346.","journal-title":"Colorectal Dis"},{"issue":"9938","key":"2153_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"19","key":"2153_CR16","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.7150\/jca.21061","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang Y, Chen W, Hu C, et al. Albumin and fibrinogen combined prognostic grade predicts prognosis of patients with prostate cancer. J Cancer. 2017;8(19):3992\u20134001.","journal-title":"J Cancer"},{"issue":"3","key":"2153_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.prnil.2017.05.001","volume":"5","author":"S \u00c7al\u0131\u015fkan","year":"2017","unstructured":"\u00c7al\u0131\u015fkan S, Sungur M. Fibrinogen and D-dimer levels in prostate cancer: preliminary results. Prostate Int. 2017;5(3):110\u20132.","journal-title":"Prostate Int"},{"issue":"1","key":"2153_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clgc.2019.10.025","volume":"18","author":"X Li","year":"2020","unstructured":"Li X, Shu K, Zhou J, et al. Preoperative plasma fibrinogen and D-dimer as prognostic biomarkers for non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2020;18(1):11\u2013e191.","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"2153_CR19","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.1002\/cam4.3086","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, He Z, Ma S, Liu R. AST\/ALT ratio as a significant predictor of the incidence risk of prostate cancer. Cancer Med. 2020;9(15):5672\u20137.","journal-title":"Cancer Med"},{"issue":"20","key":"2153_CR20","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.3390\/cancers15204907","volume":"15","author":"S Gaal","year":"2023","unstructured":"Gaal S, Huang K, Rogasch JMM, et al. Prognostic value of the de ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [177Lu] Lu-PSMA-617 radioligand therapy. Cancers (Basel). 2023;15(20):4907.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2153_CR21","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.1038\/s41598-023-42711-z","volume":"13","author":"Y Mitsui","year":"2023","unstructured":"Mitsui Y, Yamabe F, Hori S, et al. Longitudinal change in castration-resistant prostate cancer biomarker AST\/ALT ratio reflects tumor progression. Sci Rep. 2023;13(1):15292.","journal-title":"Sci Rep"},{"issue":"1","key":"2153_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s40001-023-01562-0","volume":"28","author":"ZW Yu","year":"2023","unstructured":"Yu ZW, Yuan MX, Chen GJ. The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer. Eur J Med Res. 2023;28(1):587.","journal-title":"Eur J Med Res"},{"issue":"22","key":"2153_CR23","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1097\/CM9.0000000000000506","volume":"132","author":"G-S Xie","year":"2019","unstructured":"Xie G-S, Li G, Li Y, et al. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients. Chin Med J (Engl). 2019;132(22):2684\u20139.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"2153_CR24","doi-asserted-by":"publisher","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","volume":"10","author":"I Yusim","year":"2020","unstructured":"Yusim I, Krenawi M, Mazor E, et al. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020;10(1):20015.","journal-title":"Sci Rep"},{"issue":"1","key":"2153_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12885-024-12029-8","volume":"24","author":"F Cui","year":"2024","unstructured":"Cui F, Qiu Y, Xu W, et al. Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis. BMC Cancer. 2024;24(1):305.","journal-title":"BMC Cancer"},{"issue":"7","key":"2153_CR26","first-page":"1765","volume":"12","author":"S Sfoungaristos","year":"2011","unstructured":"Sfoungaristos S, Perimenis P. Implications of PSA kinetics for an adverse pathology after radical prostatectomy. Asian Pac J Cancer Prev. 2011;12(7):1765\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"18","key":"2153_CR27","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.3390\/cancers14184350","volume":"14","author":"N d\u2019Altilia","year":"2022","unstructured":"d\u2019Altilia N, Mancini V, Falagario UG, et al. A matched-pair analysis after robotic and retropubic radical prostatectomy: A new definition of continence and the impact of different surgical techniques. Cancers. 2022;14(18):4350.","journal-title":"Cancers"},{"issue":"6","key":"2153_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.eururo.2025.01.015","volume":"87","author":"P Ravi","year":"2025","unstructured":"Ravi P, Kwak L, Acosta AM, et al. Long-term outcomes and prognostic impact of residual cancer burden after intensified neoadjuvant therapy in high-risk prostate cancer. Eur Urol. 2025;87(6):643\u201350.","journal-title":"Eur Urol"},{"issue":"10","key":"2153_CR29","doi-asserted-by":"publisher","first-page":"109665","DOI":"10.1016\/j.celrep.2021.109665","volume":"36","author":"AK Tewari","year":"2021","unstructured":"Tewari AK, Cheung ATM, Crowdis J, et al. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep. 2021;36(10):109665.","journal-title":"Cell Rep"},{"issue":"6","key":"2153_CR30","doi-asserted-by":"publisher","first-page":"e14099","DOI":"10.1111\/ijcp.14099","volume":"75","author":"S Arakoc","year":"2021","unstructured":"Arakoc S, Celik S, Kaya N, et al. Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy. Int J Clin Pract. 2021;75(6):e14099.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"2153_CR31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.euf.2023.05.005","volume":"9","author":"R Bernardino","year":"2023","unstructured":"Bernardino R, Sayyid RK, Al-Daqqaq Z, et al. Lymphotropic Pattern of Prostate-specific Membrane Antigen\u2013detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease. Eur Urol Focus. 2023;9(6):1016\u201323.","journal-title":"Eur Urol Focus"},{"issue":"8","key":"2153_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/pros.23326","volume":"77","author":"T S\u00e6ter","year":"2017","unstructured":"S\u00e6ter T, Vlatkovic L, Waaler G, et al. Intraductal carcinoma of the prostate on diagnostic needle biopsy predicts prostate cancer mortality: a population-based study. Prostate. 2017;77(8):859\u201365.","journal-title":"Prostate"},{"issue":"1","key":"2153_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/iju.15299","volume":"31","author":"Y Naito","year":"2024","unstructured":"Naito Y, Kato M, Nagayama J, et al. Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate. Int J Urol. 2024;31(1):7\u201316.","journal-title":"Int J Urol"},{"key":"2153_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.euros.2025.09.015","volume":"82","author":"RM Bernardino","year":"2025","unstructured":"Bernardino RM, Yin LB, Lajkosz K, et al. Intraductal carcinoma predicts poor response to neoadjuvant therapy in high-risk prostate cancer: A retrospective analysis of a prospective trial. Eur Urol Open Sci. 2025;82:52\u20138.","journal-title":"Eur Urol Open Sci"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02153-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:50:33Z","timestamp":1781650233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02153-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02153-x","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Research Ethics Committee of Guangdong Provincial People\u2019s Hospital and in accordance with the Declaration of Helsinki, KY-Z-2022-354-01. Due to the retrospective nature of the study and complete anonymization of data, the requirement for informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}